


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1. **(Currently Amended)** A method for treating a subject for glaucoma, comprising:
administering a therapeutically effective amount of a deprenyl compound to a subject,
wherein said deprenyl compound is represented by the structure



in which

R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl;

R₂ is hydrogen or alkyl;

R₃ is a single bond, alkylene, or $-(\text{CH}_2)_n-\text{X}-(\text{CH}_2)_m-$;

in which X is O, S, or N-methyl; m is 1 or 2; and n is 0, 1, or 2;

R₄ is alkyl, alkenyl, alkynyl, heterocyclyl, aryl or aralkyl; and

R₅ is alkylene, alkenylene, alkynylene and alkoxylenylene; and

R₆ is C₃-C₆ cycloalkyl or



R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof;

such that the subject is treated for glaucoma.


2. **(Cancelled)**

3. **(Currently Amended)** The method of claim 2 1, wherein R₁ is a group that can be removed *in vivo*.

4. **(Currently Amended)** The method of claim 2 1, wherein R₁ is hydrogen.
5. **(Currently Amended)** The method of claim 2 1, wherein R₁ is alkyl.
6. **(Original)** The method of claim 5, wherein R₁ is methyl.
7. **(Currently Amended)** The method of claim 2 1, wherein R₂ is methyl.
8. **(Currently Amended)** The method of claim 2 1, wherein R₃ is methylene.
9. **(Currently Amended)** The method of claim 2 1, wherein R₄ is aryl.
10. **(Currently Amended)** The method of claim 2 1, wherein R₄ is phenyl.
11. **(Currently Amended)** The method of claim 2 1, wherein R₅ is methylene.
12. **(Currently Amended)** The method of claim 2 1, wherein R₆ is




13. **(Currently Amended)** The method of claim 2 1, wherein the deprenyl compound has the structure



wherein R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl.

14. **(Currently Amended)** The method of claim 2 1, wherein the deprenyl compound is represented by the structure:



in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl;

R_2 is hydrogen or alkyl;


R_3 is a bond or methylene; and

R_4 is aryl or aralkyl; or

R_2 and R_4-R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

15. **(Currently Amended)** The method of claim 2 1, wherein the deprenyl compound is represented by the structure:



in which

R_2 is hydrogen or alkyl;

R_3 is a bond or methylene; and


R_4 is aryl or aralkyl; or

R_2 and R_4-R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group; and

R_5 is alkylene, alkenylene, alkynylene and alkoxylenylene;

and pharmaceutically acceptable salts thereof.

16. **(Currently Amended)** The method of claim 2 1, wherein the deprenyl compound is represented by the structure:



in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxy carbonyl;

A is a substituent independently selected for each occurrence from the group consisting of halogen, hydroxyl, alkyl, alkoxy, cyano, nitro, amino, carboxyl, $-CF_3$, or azido;

n is 0 or an integer from 1 to 5;

and pharmaceutically acceptable salts thereof.

17. **(Original)** The method of claim 1, wherein the deprenyl compound is (-)-deprenyl.
18. **(Original)** The method of claim 1, wherein the deprenyl compound is (-)-pargyline.
19. **(Original)** The method of claim 1, wherein the deprenyl compound is (-)-desmethyldeprenyl.
20. **(Cancelled)**